Plasminogen activation in synovial tissues: Differences between normal, osteoarthritis, and rheumatoid arthritis joints

Annals of the Rheumatic Diseases

Volumn 56, Issue 9, 1997, Pages 550-557

  Busso, Nathalie ^a   Péclat, Véronique ^a   So, Alexander ^a   Sappino, André Pascal ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ARTICLE; CONTROLLED STUDY; ENZYME ASSAY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; NORTHERN BLOTTING; OSTEOARTHRITIS; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; RHEUMATOID ARTHRITIS; RNA ANALYSIS; SYNOVIUM; TISSUE DISTRIBUTION;

EID: 0030805452     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.56.9.550     Document Type: Article

References (44)

1. Harris ED. Etiology and pathogenesis of rheumatoid arthritis. In: Kelley WN, Harris ED, Ruddy S, Sledge CB, eds. Textbook of rheumatology. Philadelphia: WB Saunders, 1993: 833-73.
2. Zvaifler NJ, Firestein GS. Pannus and pannocytes: Alternative models of joint destruction in rheumatoid arthritis. Arthritis Rheum 1994;37:783-9.
3. Brandt KD, Mankin HJ. Pathogenesis of osteoarthritis. In: Kelley WN, Harris ED, Ruddy S, Sledge CB, eds. Textbook of rheumatology. Philadelphia: WB Saunders, 1993:1355-73.
4. Freemont AJ. Histopathology of the rheumatoid joint. In: Henderson B, Edwards JCW, Pettipher ER, eds. Mechanisms and models in rheumatoid arthritis. San Diego: Academic Press, 1995: 83-113.
5. Werb Z, Alexander CM. Proteinases and matrix degradation. In: Kelley WN, Harris ED, Ruddy S, Sledge CB, eds. Textbook of rheumatology. Philadelphia: WB Saunders, 1993: 248-68.
6. Vassalli JD, Sappino AP, Belin D. The plasminogen activator, plasmin system. J Clin Invest 1991;88:1067-72.
7. Murphy G, Atkinson S, Ward R, Gavrilovic J, Reynolds JJ. The role of plasminogen activators in the regulation of connective tissue metalloproteinases. Ann NY Acad Sci 1992;667:1-12.
8. Andreasen PA, Georg B, Lund LR, Riccio A, Stacey SN. Plasminogen activator inhibitors: hormonally regulated serpins. Mol Cell Endocrinol 1990;88:1-19.
9. Vassalli JD, Baccino D, Belin D. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol 1985;100:86-92.
10. Ellis V, Scully MF, Kakkar W. Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes. J Biol Chem 1989;264:2185-8.
11. Ossowski L, Clunie G, Masucci MT, Blasi F. In vivo paracrine interaction between uokinase and its receptor: effect on tumor cell invasion. J Cell Biol 1991;115:1107-12.
12. Crowley CW, Cohen RL, Lucas BK, Liu G, Shuman MA, Levinson AD. Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Sci USA 1993;90:5021-5.
13. Brommer EJ, Dooijewaard G, Dijkmans BA, Breedveld FC. Depression of tissue-type plasminogen activator and enhancement of urokinase-type plasminogen activator as an expression of local inflammation. Thromb Haemost 1992;68:180-4.
14. Kummer JA, Abbink JJ, de Boer JP, Roem D, Nienwenhuys EJ, Kamp AM, et al. Analysis of intraarticular fibrinolytic pathways in patients with inflammatory and noninflammatory joint diseases. Arthritis Rheum 1992;35:884-93.
15. Saxne T, Lecander I, Geborek P. Plasminogen activators and plasminogen activator inhibitors in synovial fluid. Difference between inflammatory joint disorders and osteoarthritis. J Rheumatol 1993;20:91-6.
16. Belcher C, Fawthrop F, Bunning R, Doherty M. Plasminogen activators and their inhibitors in synovial fluid from normal, osteoarthritis, and rheumatoid arthritis knees. Ann Rheum Dis 1996;55:230-6.
17. Bromrner EJ, Dooijewaard G, Dijkmans BA, Breedveld FC. Plasminogen activators in synovial fluid and plasma from patients with arthritis. Ann Rheum Dis 1992;51:965-8.
18. Kikuchi H, Tanaka S, Matsuo O. Plasminogen activator in synovial fluid from patients with rheumatoid arthritis. J Rheumatol 1987;14:439-45.
19. Matsuo O, Tanaka S, Kikuchi H. Effect of urinary trypsin inhibitor on osteoarthritis. Thromb Res 1988;52:237-45.
20. Weinberg JB, Pippen AM, Greenberg CS. Extravascular fibrin formation and dissolution in synovial tissue of patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 1991;34:996-1005.
21. Ronday HK, Smits HH, van Muijen GN, Pruszcynski MS, Dolhain RJ, van Langelaan EJ, et al. Difference in expression of the plasminogen activation system in synovial tissue of patients with rheumatoid arthritis and osteoarthritis. Br J Rheumatol 1996;35:416-23.
22. Hamilton JA, Campbell IK, Wojta J, Cheung D. Plasminogen activators and their inhibitors in arthritic disease. Ann NY Acad Sci 1991;667:87-100.
23. Martel-Pelletier J, Faure MP, McCollum R, Mineau F, Cloutier JM. Plasmin, plasminogen activators and inhibitor in human osteoarthritic cartilage. J Rheumatol 1991;18: 1863-71.
24. Altman RD. Criteria for classification of clinical osteoarthritis. J Rheumatol 1991;18:10-2.
25. Arnett FC, Edworthy SM, Bloch DA. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
26. Sappino AP, Huarte J, Vassalli JD, Belin D. Sites of synthesis of urokinase and tissuetype plasminogen activators in the murine kidney. J Clin Invest 1991;87:962-70.
27. Delbaldo C, Cunningham M, Vassalli JD, Sappino AP. Plasmin-catalyzed proteolysis in colorectal neoplasia. Cancer Res 1995;55:4688-95.
28. Vassalli JD, Belin D. Amiloride selectively inhibits the urokinase-type plasminogen activator. FEBS Lett 1987;214:187-91.
29. Busso N, Belin D, Failly-Crepin C, Vassalli JD. Glucocorticoid modulation of plasminogen activators and of one of their inhibitors in the human mammary carcinoma cell line MDA-MB-231. Cancer Res 1987;47:364-70.
30. Kristensen P, Eriksen J, Blasi F, Dano K. Two alternatively sliced mouse urokinase receptor mRNAs with different histological localization in gastrointestinal tract. J Cell Biol 1991;115:1763-71.
31. Keyszer GM, Heer AH, Gay S. Cytokines and oncogenes in cellular interactions of rheumatoid arthritis. Stem Cells 1994;12:75-86.
32. Dooley S, Herlitzka I, Hanselmann R, Ermis A, Henn W, Remberger K, et al. Constitutive expression of c-fos and c-jun overexpression of ets-2, and reduced expression of metastasis suppressor gene nm23-H1 in rheumatoid arthritis. Ann Rheum Dis 1996;55:298-304.
33. Macleod K, Leprince D, Stehelin D. The ets gene family. Trends Biochem Sci 1992;17:251-6.
34. Delbaldo C, Masonye I, Saurat JH, Vassalli JD, Sappino AP. Plasminogen activation in melanocytic neoplasia. Cancer Res 1994;54:4547-52.
35. de Vries TJ, Quax PH, Denijn M, Verrijp KN, Verheijen JH, Verspaget HW, et al. Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. Am J Pathol 1994;144:70-81.
36. Sappino AP, Belin D, Huarte J, Hirschel-Scholz S, Saurat JH, Vassalli JD. Differential protease expression by cutaneous squamous and basal cell carcinomas. J Clin Invest 1991;88:1073-9.
37. Sato YR, Rifkin DB. Inhibition, of endothelial cell movement by perycites and smooth muscle cells: Activation of a latent transforming growth factor 1-like molecule by plasmin during co-culture. J Cell Biol 1989;109:309-15.
38. Naldini L, Tamagnone L, Vigna E, Sachs M, Hartmann G, Birchmeier W, et al. Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor scatter factor. EMBO J 1992;11:4825-33.
39. Gyetko MR, Chen GH, McDonald RA, Goodman R. Huffnagle GB, Wilkinson CC, et al. Urokinase is required for the pulmonary inflammatory response to Cryptococcus neoformans: A murine transgenic model. J Clin Invest 1996;97:1818-26.
40. Gyetko M, Todd R, Wilinson C, Sitrin RG. The urokinase receptor is required for human monocyte chemotaxis in vitro. J Clin Invest 1994;93:1380-7.
41. Waltz DA, Sailor LZ, Chapman HA. Cytokines induce urokinase-dependent adhesion of human myeloid cells. A regulatory role for plasminogen activator inhibitors. J Clin Invest 1993;91:1541-52.
42. Rabbani SA, Mazar AP, Bernier SM, Haq M, Bolivar I, Henkin J, et al. Structural requirements for the growth factor activity of the amino-terminal domain of urokinase activity. FEBS Lett 1992;267:14151-6.
43. Carmeliet P, Schoonjans L, Kieckens L, Ream B, Degen J L, Bronson R, et al. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994;368:419-24.
44. Bugge TH, Flick MJ, Daugherty CC, Degen JL. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction Genes Dev 1995;9:794-807.